Effects of the strong CYP3A4 and P-glycoprotein inhibitor itraconazole on the pharmacokinetics of oral and intranasal zavegepant

被引：0
|
作者：
Bhardwaj, R. [1 ]
Malatesta, J. K. [2 ]
Stringfellow, J. [3 ]
Madonia, J. [4 ]
Anderson, M. [4 ]
Stock, D. A. [4 ]
Morris, B. A. [4 ]
Coric, V [5 ]
Croop, R. [5 ]
Bertz, R. [4 ]
机构：
[1] Certara Strateg Consulting, Integrated Drug Dev, Princeton, NJ USA
[2] Certara USA, Princeton, NJ USA
[3] Navitas Data Sci, Pottstown, PA USA
[4] Biohaven Pharmaceut, New Haven, CT USA
[5] Biohaven Pharmaceut Holding Co Ltd, New Haven, CT USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-163
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [41] Effects of Myricetin on the Bioavailability of Doxorubicin for Oral Drug Delivery in Rats: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Myricetin
    Choi, Sang-Joon
    Shin, Sang-Chul
    Choi, Jun-Shik
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (02) : 309 - 315
  • [42] Plasma concentrations of quinidine are determined by intestinal P-glycoprotein and CYP3A4 in humans
    Drescher, S
    Glaeser, H
    Mürdter, T
    Eichelbaum, M
    Fromm, MF
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2003, 367 : R114 - R114
  • [43] The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4
    Wang, Xianming
    Zhang, Xiang
    Huang, Xinhui
    Li, Yuntong
    Wu, Mengchao
    Liu, Jingfeng
    XENOBIOTICA, 2016, 46 (07) : 651 - 658
  • [44] Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin
    Dong-Hyun Choi
    Jin-Seok Choi
    Cheng Li
    Jun-Shik Choi
    Pharmacological Reports, 2011, 63 (6) : 1574 - 1582
  • [45] Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin
    Choi, Dong-Hyun
    Choi, Jin-Seok
    Li, Cheng
    Choi, Jun-Shik
    PHARMACOLOGICAL REPORTS, 2011, 63 (06) : 1574 - 1582
  • [46] Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis
    Yang, Siyu
    Xu, Ye
    Zhang, Yang
    Li, Dandan
    Li, Xingang
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (15) : 1167 - 1177
  • [47] Expression of P-glycoprotein and CYP3A4 along the porcine oral-gastrointestinal tract: implications on oral mucosal drug delivery
    Gao, Xiaoling
    Bhattacharya, Shiladitya
    Chan, William K.
    Jasti, Bhaskara R.
    Upadrashta, Bala
    Li, Xiaoling
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2014, 40 (05) : 599 - 603
  • [48] Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin
    Cho, Y. A.
    Lee, W.
    Choi, J. S.
    PHARMAZIE, 2012, 67 (02): : 124 - 130
  • [49] Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
    Shimizu, Mikiko
    Uno, Tsukasa
    Sugawara, Kazunobu
    Tateishi, Tomonori
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) : 372 - 376
  • [50] Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
    Bhardwaj, RK
    Glaeser, H
    Becquemont, L
    Klotz, U
    Gupta, SK
    Fromm, MF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02): : 645 - 650
12345